Clinical Trial Update: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of oral venetoclax and intravenous obinutuzumab in adults with recurring chronic lymphocytic leukemia is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Gazyva (Obinutuzumab)
• Venclyxto (Venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Status: RECRUITING